Please assess the completion status of the following clinical trial:

Trial Title: Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis ADHD based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR)~* At least 1.5 standard deviations above the age norm for their diagnostic subtype using published norms for the ADHD Rating Scale-IV-Parent Version~* Cannabis Abuse or dependence based on the DSM-IV-TR, and using a minimum of 5 joints per week~Exclusion Criteria:~* Weight under 20 kilograms (kg)~* Patients at serious suicidal risk~* Patients with alcohol or drug abuse (other than cannabis)~* Patients who in the investigator's judgement are likely to need psychotropic medication + psychotherapy apart from atomoxetine

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Atomoxetine (Type: EXPERIMENTAL): 0.5 milligrams per kilogram (mg/kg) daily for 1 week followed by 1.2 mg/kg daily for 11 weeks, orally, capsules.

Based on this trial design, predict the completion outcome and termination type (if applicable).